Shun Lu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Shun Lu has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Hong Jian
Shanghai Lung Tumor Clinical Medical Center Shanghai Chest Hospital Shanghai Jiao Tong University China
1 shared publication Yi Yang
Shanghai Lung Tumor Clinical Medical Center Shanghai Chest Hospital Shanghai Jiao Tong University China
1 shared publicationYi Zhao
Shanghai Lung Tumor Clinical Medical Center Shanghai Chest Hospital Shanghai Jiao Tong University China
1 shared publicationYunhua Xu
Shanghai Lung Tumor Clinical Medical Center Shanghai Chest Hospital Shanghai Jiao Tong University China
1 shared publication
Latest Publications
- Open Access
- 10 March 2017
- Published by Wiley in FEBS Open Bio
- Vol. 7 (4) , 472-476
AZD0530 sensitizes drug‐resistantALK‐positive lung cancer cells by inhibitingSRCsignaling
Most tumors develop resistance to targeted cancer drugs, even though these drugs have produced substantial clinical responses. Here we established anaplastic lymphoma kinase (ALK)‐positive drug‐resistant lung cancer cell lines, which are resistant to ceritinib (LDK378). We found that ceritinib treatment resulted in robust upregulation ofSRCactivity, as measured by the phosphorylation of theSRCsubstrate paxillin. Knockdown ofSRCalone with siRNAeffectively sensitized ceritinib resistance inALK‐positive cells. Furthermore,SRCinhibition byAZD0530 was effective inALK‐resistant cancer cells. Thus,ALKinhibition by ceritinib may lead to upregulation ofSRCsignaling, andAZD0530 could serve as a potential drug in the clinic to treatALK‐resistant lung cancer patients.
- 10 March 2017
- Published by Wiley in FEBS Open Bio
- Vol. 7 (4) , 472-476
Open AccessAZD0530 sensitizes drug‐resistantALK‐positive lung cancer cells by inhibitingSRCsignaling
Most tumors develop resistance to targeted cancer drugs, even though these drugs have produced substantial clinical responses. Here we established anaplastic lymphoma kinase (ALK)‐positive drug‐resistant lung cancer cell lines, which are resistant to ceritinib (LDK378). We found that ceritinib treatment resulted in robust upregulation ofSRCactivity, as measured by the phosphorylation of theSRCsubstrate paxillin. Knockdown ofSRCalone with siRNAeffectively sensitized ceritinib resistance inALK‐positive cells. Furthermore,SRCinhibition byAZD0530 was effective inALK‐resistant cancer cells. Thus,ALKinhibition by ceritinib may lead to upregulation ofSRCsignaling, andAZD0530 could serve as a potential drug in the clinic to treatALK‐resistant lung cancer patients.